Salvianolic Acid B Slows the Progression of Breast Cancer Cell Growth via Enhancement of Apoptosis and Reduction of Oxidative Stress, Inflammation, and Angiogenesis
Open Access
- 12 November 2019
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (22), 5653
- https://doi.org/10.3390/ijms20225653
Abstract
Breast cancer is the current leading cause of cancer death in females worldwide. Although current chemotherapeutic drugs effectively reduce the progression of breast cancer, most of these drugs have many unwanted side effects. Salvianolic acid B (Sal-B) is a bioactive compound isolated from the root of Danshen Radix with potent antioxidant and anti-inflammatory properties. Since free radicals play a key role in the initiation and progression of tumor cells growth and enhance their metastatic potential, the current study was designed to investigate the antitumor activity of Sal-B and compare it with the antitumor activity of the traditional anticancer drug, cisplatin. In vitro, Sal-B decreased the human breast cancer adenocarcinoma (MCF-7) cells proliferation in a concentration and time dependent manner. In vivo and similar to cisplatin treatment, Sal-B significantly reduced tumor volume and increased the median survival when compared to tumor positive control mice group injected with Ehrlich solid carcinoma cell line (ESC). Sal-B decreased plasma level of malondialdehyde as a marker of oxidative stress and increased plasma level of reduced glutathione (GSH) as a marker of antioxidant defense when compared to control ESC injected mice. Either Sal-B or cisplatin treatment decreased tumor tissue levels of tumor necrosis factor (TNF-α), matrix metalloproteinase-8 (MMP-8), and Cyclin D1 in ESC treated mice. Contrary to cisplatin treatment, Sal-B did not decrease tumor tissue Ki-67 protein in ESC injected mice. Immunohistochemical analysis revealed that Sal-B or cisplatin treatment increased the expression of the apoptotic markers caspase-3 and P53. Although Sal-B or cisplatin significantly reduced the expression of the angiogenic factor vascular endothelial growth factor (VEGF) in ESC injected mice, only Sal-B reduced expression level of COX-2 in ESC injected mice. Our data suggest that Sal-B exhibits antitumor features against breast cancer cells possibly via enhancing apoptosis and reducing oxidative stress, inflammation, and angiogenesis.Keywords
This publication has 65 references indexed in Scilit:
- Salvianolic Acid B Prevents Arsenic Trioxide-Induced CardiotoxicityIn Vivoand Enhances Its Anticancer ActivityIn VitroEvidence-Based Complementary and Alternative Medicine, 2013
- Modulation of growth and angiogenic potential of oral squamous carcinoma cells in vitro using salvianolic acid BBMC Complementary and Alternative Medicine, 2011
- Salvianolic Acid B, a Potential Chemopreventive Agent, for Head and Neck Squamous Cell CancerJournal of Oncology, 2010
- p53: The Attractive Tumor Suppressor in the Cancer Research FieldJournal of Biomedicine and Biotechnology, 2010
- Combination Effects of Salvianolic Acid B with Low-Dose Celecoxib on Inhibition of Head and Neck Squamous Cell Carcinoma Growth In vitro and In vivoCancer Prevention Research, 2010
- Salvianolic acid B inhibits growth of head and neck squamous cell carcinoma in vitro and in vivovia cyclooxygenase‐2 and apoptotic pathwaysInternational Journal of Cancer, 2009
- Antioxidative and anti-carcinogenic activities of tea polyphenolsArchives of Toxicology, 2008
- Cancer-related inflammationNature, 2008
- ROS stress in cancer cells and therapeutic implicationsDrug Resistance Updates, 2004